Also known as: OXT, Pitocin (synthetic), Syntocinon
Half-life: ~3-5 minutes (plasma); longer central effects after intranasal
Last reviewed: · Published:
Oxytocin is a nine-amino-acid neuropeptide produced by magnocellular neurons in the paraventricular and supraoptic nuclei of the hypothalamus and released both into the bloodstream (from the posterior pituitary, acting as a hormone) and centrally onto neuronal targets throughout the brain (acting as a neurotransmitter). Its classical physiological roles are stimulating uterine contractions during labor and triggering milk ejection during breastfeeding — applications for which synthetic oxytocin (Pitocin in the US, Syntocinon in Europe) has been an FDA-approved obstetric medication since the 1960s.
Beyond reproduction, oxytocin has been extensively studied for its effects on social behavior, trust, pair bonding, emotional recognition, and stress regulation. Intranasal oxytocin (which crosses the blood-brain barrier in modest amounts) has been used in hundreds of psychological and clinical studies as a research probe. Effects on trust, in-group/out-group bias, social cognition, and anxiety have been reported in many studies — though replication of these findings has been notoriously variable, and the field has been increasingly skeptical of the early enthusiasm.
Oxytocin is sold by peptide vendors as a research compound and is used in the wellness community both intranasally (for social/emotional effects) and subcutaneously (for relaxation, libido, or post-coital bonding effects). Compounded prescription intranasal oxytocin is available in some US states for off-label psychiatric and relationship-counseling uses. The peptide is generally well-tolerated but the magnitude and consistency of the subjective effects are far less reliable than the marketing narrative would suggest.
Oxytocin was the first peptide hormone to be sequenced and synthesized — Vincent du Vigneaud accomplished both in the early 1950s, work for which he received the 1955 Nobel Prize in Chemistry. Synthetic oxytocin (Pitocin) became an obstetric standard shortly thereafter. The intranasal route for CNS-targeted oxytocin emerged in research literature from the 1980s onward, with the modern explosion of social-cognition oxytocin studies beginning in the early 2000s following influential work by Andreas Meyer-Lindenberg, Markus Heinrichs, and Paul Zak.
Single-dose intranasal oxytocin in research is generally very well-tolerated, with the main complaints being nasal irritation or mild headache. Clinical IV oxytocin in obstetric use has a well-characterized safety profile when properly dosed. Subcutaneous oxytocin in wellness use is generally well-tolerated but lacks the safety data of the established obstetric and intranasal-research formulations. The most important caveat is psychological: subjective responses to oxytocin are highly variable and the social effects are not as robust as commonly claimed.
Dose Range
24-40 IU
Frequency
As needed, typically 30-45 min before relevant activity
Duration
Acute use
Dose Range
5-10 IU
Frequency
As needed
Duration
Acute use
Dose Range
Per obstetric protocol
Frequency
Titrated infusion
Duration
Per delivery
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
2 mg
Water Type
Bacteriostatic water (BAC water) or sterile saline for intranasal
Mixing Volume
2 mL
Half-Life
~3-5 minutes (plasma); longer central effects after intranasal
Molecular Weight
1,007 Da
Store reconstituted vial refrigerated at 2-8°C. Use within 14-21 days. Intranasal administration via metered spray is the most common research route. Note that conversion between mcg and IU varies by formulation; check vendor specification.
FDA Status
FDA approved as injectable Pitocin for obstetric indications since the 1960s. Intranasal oxytocin not FDA-approved as therapeutic; available via compounding pharmacies.
Legal Status
Prescription drug in obstetric / clinical formulations. Research chemical in vendor-sold form. Prohibited by WADA.
USA
Approved (Pitocin)IV for labor induction; intranasal via compounding
EU
Approved (Syntocinon)IV for obstetric use; intranasal previously available, now off-label
UK
Approved (Syntocinon)IV obstetric use
Australia
Approved (Syntocinon)IV obstetric use
Canada
Approved (Pitocin / Syntocinon)IV obstetric use
Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E
Nature (2005)
Influential (though contested in replication) study demonstrating that intranasal oxytocin increased trust behavior in an economic game in healthy male volunteers — the paper that launched the modern wave of social-cognition oxytocin research.
View Study →Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M
Journal of Neuroendocrinology (2011)
Authoritative review of oxytocin's effects on human social cognition, including discussion of the inconsistencies and replication concerns that have moderated the field's early enthusiasm.
View Study →Smyth RM, Markham C, Dowswell T
Cochrane Database of Systematic Reviews (2013)
Cochrane systematic review of obstetric oxytocin use establishing its place as a standard of care for labor induction and confirming its safety profile in supervised clinical use.
View Study →Track Oxytocin and more with PinnyPeptide.
Sign Up to Track OxytocinFree forever · defaults pre-filled from this article